ACM
MLTX icon

ADAR1 Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

ADAR1 Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,000
Closed -$373K – 321
2026
Q1 		$373K Buy
+20,000
New +$331K 0.02% 223
2025
Q4 		– Sell
-17,000
Closed -$122K – 285
2025
Q3 		$122K Buy
+17,000
New +$886K 0.01% 198

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ADAR1 Capital Management's MLTX Position: Q2 2026 in Review

ADAR1 Capital Management reduced its MoonLake Immunotherapeutics (MLTX) stake by 94% in Q2 2026, selling an estimated $7.8M and leaving 27,000 shares worth $526K. The position accounts for 0.02% of the portfolio, ranked #208.

ADAR1 Capital Management first reported a position in MLTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $8.52M in Q1 2026. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • ADAR1 Capital Management held 27,000 shares of MoonLake Immunotherapeutics worth $526K as of Q2 2026.
  • ADAR1 Capital Management sold 430,137 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $7.8M.
  • MoonLake Immunotherapeutics made up 0.02% of ADAR1 Capital Management's portfolio in Q2 2026, its #208 holding.
  • ADAR1 Capital Management first reported a position in MoonLake Immunotherapeutics in Q1 2024 and has held it in 9 quarters since.
  • ADAR1 Capital Management's MoonLake Immunotherapeutics position peaked at $8.52M in Q1 2026.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.